Home » Newsletters » BioWorld Science

BioWorld Science

July 29, 2005

View Archived Issues

Potent candidate for EGFR overexpressing tumors identified

Xanodyne completes acquisition of aaiPharma products

Novel mGluR1 antagonist evokes analgesia

Cellzome and Novartis expand pathway research collaboration

Clinical trials support the use of certolizumab in active Crohn's disease

Preclinical evidence suggests estrogen receptors play a role in gonadotropin-induced fertility

Tempol improves dopamine D1 receptor dysfunction in obese rats

Chunghyuldan lowers systolic blood pressure in stroke patients

Identification of a potent and selective histamine H4 receptor agonist

Transkaryotic Therapies stockholders approve acquisition by Shire

Schering AG and AstraZeneca form antiinflammatory collaboration

Twinstrand Therapeutics cleared for U.S. clinical development of TST-10088

Japanese phase I trial of NFkB decoy oligo for atopic dermatitis cleared to begin

Valeant plans phase III trials for retigabine for partial-onset seizures

ZARS receives approval for Synera topical local anesthetic patch

Phase Ib study examines GI-5005 for chronic HCV

GRN-163L enters clinical trial in CLL patients

Japanese approval for Finibax

Allegra-D 24 Hour now available

Encysive submits Thelin MAA

Submission of Ranexa NDA amendment

European CHMP hands down positive opinion for tipranavir

Fast track designation for TAK-242 for severe sepsis

NDA accepted for Wyeth's new oral contraceptive

Novel therapeutics for cardiovascular diseases reported

Melanocortin MC4 receptor agonists in early development at Novo Nordisk

Kyoto University discloses novel therapeutic agents for eating disorders